DOI: 10.3724/SP.J.1264.2011.00016

Chinese Journal of Multiple Organ Diseases in the Elderly (中华老年多器官疾病杂志) 2011/10:4 PP.348-352

Effects of valsartan on sarcoplasmic reticulum calcium adenodine triphosphatase expression and function in a rabbit model of heart failure

Objective To investigate the effects of valsartan on sarcoplasmic reticulum calcium adenodine triphosphatase expression and function in a rabbit model of heart failure. Methods Twenty-seven rabbits were divided into sham-operated, heart failure and valsartan groups, with 9 in each group. The rabbit model of heart failure was prepared by volume overload plus pressure overload. After 7 weeks, left ventricular function, hemodynamic parameters, and expression and function of SERCA2 were observed. Results Compared with sham-operated rabbits, left ventricular mass index (LVMI)and left ventricular end diastolic pressure (LVEDP)were significantly increased in heart failure rabbits [(1.32±0.06) vs (3.61±0.09)g/kg and (-0.50±1.05) vs (23.00±2.37)mmHg respectively, P<0.05=, but the left ventricular shortening fraction and left ventricular ejection fraction (LVEF)were significantly decreased in heart failure rabbits [(37.83±3.58)% vs (17.38±3.13)%; (72±5)% vs (38±6)%, P<0.05=. Compared with heart failure rabbits, LVMI and LVEDP were significantly decreased in valsartan rab-bits [(2.07±0.14)g/kg and (2.17±0.72)mmHg respectively, P<0.05=, but their left ventricular shortening fraction and LVEF were increased [(33.8±2.9)% and (65±4)% respectively, P<0.05=. Expression and function of SERCA2 were remarkably lower in heart failure rabbits than in sham-operated rabbits [(0.69±0.04) vs (1.02±0.02)and (54.4±7.9)% vs (95.5±2.1)% respectively, P<0.05=, while compared with heart failure rabbits, they were significantly higher in valsartan rabbits [(0.91±0.02)and (81.7±4.9)% respectively, P<0.05)]. Conclusion Valsartan can improve cardiac function, probably owing to its roles in upregulating expression and function of SERCA2 in the prevention of heart failure.

Key words:valsartan,heart failure, congestive,sarcoplasmic reticulum,Ca(2+)-transporting ATPase

ReleaseDate:2014-07-21 15:56:23

[1] Guo X, Chapman D, Dhalla NS. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan[J]. Mol Cell Biochem, 2003, 254(1-2): 163-172.

[2] Periasamy M, Bhupathy P, Babu GJ. Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology[J]. Cardiovasc Res, 2008, 77(2): 265-273.

[3] Ju H, Scammel-La Fleur T, Dixon IM. Altered mRNA abundance of calcium transport genes in cardiac myocytes induced by angiotensin II[J]. J Mol Cell Cardiol, 1996, 28(5): 1119-1128.

[4] Shao Q, Ren B, Saini HK, et al. Sarcoplasmic re-ticulum Ca2+ transport and gene expression in congestive heart failure are modified by imidapril treatment[J]. Am J Physiol Heart Circ Physiol, 2005, 288(4): H1674-H1682.

[5] 邹 操, 刘志华, 赵彩明, 等. 超容量负荷联合压力负荷制备家兔心力衰竭模型的可行性探讨[J]. 实验动物与比较医学, 2005, 25(4): 211-214.

[6] Jones LR, Simmerman HK, Wilson WW, et al. Purification and characterization of phospholamban from ca-nine cardiac sarcoplasmic reticulum [J]. J Biol Chem, 1985, 260(12): 7721-7730.

[7] Dibb KM, Graham HK, Venetucci LA, et al. Analy-sis of cellular calcium fluxes in cardiac muscle to understand calcium homeostasis in the heart[J]. Cell Calcium, 2007, 42(4-5): 503-512.

[8] Xu YJ, Chapman D, Dixon IM, et al. Differential gene expression in infarct scar and viable myocardium from rat heart following coronary ligation[J]. J Cell Mol Med, 2004, 8(1): 85-92.

[9] Zhao XY, Hu SJ, Li J, et al. rAAV-asPLB transfer attenuates abnormal sarcoplasmic reticulum Ca2+ ATPase activity and cardiac dysfunction in rats with myocardial infarction[J]. Eur J Heart Fail, 2008, 10(1): 47-54.

[10] Oishi Y, Ozino R, Yoshizumi M, et al. AT2 receptor mediates the cardioprotective effects of AT1 receptor an-tagonist in post-myocardial infarction remodeling[J]. Life Sci, 2006, 80(1): 82-88.

[11] Cohn JN, Tognoni G. A randomized trial of the angiotensin- receptor blocker valsartan in chronic heart failure[J]. N Engl J Med, 2001, 345(23): 1667-1675.

[12] Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall pro-gramme[J]. Lancet, 2003, 362(9386): 759-766.